XML 26 R9.htm IDEA: XBRL DOCUMENT
v3.25.1

Balance Sheet Accounts | 6 Months Ended
--- | ---
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Accounts | BALANCE SHEET ACCOUNTS Property, Plant and Equipment The following table summarizes the Company’s major classes of property, plant and equipment:
| March 31, 2025 |  | September 30, 2024
| (in thousands)
Land | $ | 2,996 |  |  | $ | 2,996 |
Buildings | 248,893 |  |  | 75,988 |
Research equipment | 60,259 |  |  | 65,353 |
Manufacturing equipment | 13,812 |  |  | — |
Furniture | 5,594 |  |  | 5,594 |
Computers and software | 1,033 |  |  | 981 |
Leasehold improvements | 104,401 |  |  | 104,410 |
Construction in progress | 16,245 |  |  | 188,731 |
| 453,233 |  |  | 444,053 |
Less: Accumulated depreciation and amortization | (68,430) |  |  | (58,021) |
Property, plant and equipment, net | $ | 384,803 |  |  | $ | 386,032 |
Depreciation and amortization expense for property, plant and equipment for the three months ended March 31, 2025 and 2024 was $5.6 million and $4.1 million, respectively. Depreciation and amortization expense for property, plant and equipment for the six months ended March 31, 2025 and 2024 was $10.4 million and $7.9 million, respectively. During the first quarter of fiscal 2025, the Company completed the build out of its manufacturing facility in Verona, Wisconsin. This resulted in the reclassification of $172.9 million from construction in progress to buildings and $13.8 million to manufacturing equipment as of March 31, 2025. Additionally, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods. During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $76.0 million from construction in progress to buildings as of March 31, 2025. Accrued Expenses Accrued expenses consisted of the following as of:
| March 31, 2025 |  | September 30, 2024
| (in thousands)
Accrued R&D expenses | $ | 42,963 |  |  | $ | 28,069 |
Accrued R&D expenses; co-development | 28,755 |  |  | 23,351 |
Accrued capital expenditures | 358 |  |  | 4,206 |
Other | 6,374 |  |  | 7,391 |
Total accrued expenses | $ | 78,450 |  |  | $ | 63,017 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration